Moonlake Immunotherapeutics (MLTX)

Moonlake Immunotherapeutics Stock (MLTX) dropped by 29.11% from $51.28 to $36.35 in the trading on Monday November 6, 2023. The reason why MLTX stock down today is due to the topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with active psoriatic arthritis (PsA). The company said that the 207-patient trial met its primary endpoint with a statistically significant effect while the 60mg dose without induction did not reach statistical significance for the primary endpoint. Although the trial was positive, it was difficult to reach conclusions without seeing placebo response rates and analyzing additional details.

MoonLake Immunotherapeutics (MLTX) stock was down 6.32% after it filed a shelf registration statement for the potential sale of up to $1 billion of its securities from time to time.

https://twitter.com/AInvestOfficial/status/1697724526652477747